利福布汀与利福喷丁治疗大鼠异物骨髓炎MRSA感染的新探索
本研究在大鼠异物骨髓炎模型中评估利福布汀、利福喷丁和利福平(单用或联用万古霉素)抗MRSA效果。感染4周后给药,利福布汀或利福喷丁联合万古霉素在骨与克氏针上的MRSA载量低于未治疗或单用万古霉素,与利福平联合万古霉素相当。提示二者或可作为利福平的替代用于假体周围关节感染。
要点
- 利福布汀或利福喷丁联合万古霉素可显著降低骨与异物上的MRSA载量。
- 联合方案效果与利福平联合万古霉素相当,单用利福平组出现1例耐药。
- 结果支持二者作为利福平替代用于葡萄球菌假体周围关节感染的潜力。
核心结论
- 在大鼠异物骨髓炎模型中,利福布汀或利福喷丁联合万古霉素抗MRSA活性与利福平联合万古霉素相当。
研究设计与样本
- 研究为大鼠异物骨髓炎模型,胫骨近端接种MRSA并植入克氏针,感染4周后分别给予利福平、利福布汀或利福喷丁单用或联用万古霉素。
主要发现
- 利福平、利福布汀或利福喷丁联合万古霉素组骨内MRSA中位数分别为0.10、3.02和0.10 log10 CFUs/g,低于未治疗组的4.36 log10 CFUs/g和单用万古霉素组的4.64 log10 CFUs/g(两者P ≤ .02)。
- 未治疗组和单用万古霉素组克氏针上MRSA中位数分别为1.76和2.91 log10 CFUs/K-wire,而利福平、利福布汀和利福喷丁联合万古霉素组均为0.1 log10 CFUs/K-wire。
- 利福平单药组有1只动物检出利福平耐药。
临床怎么用
- 对于葡萄球菌假体周围关节感染需替代利福平的患者,利福布汀或利福喷丁联合万古霉素可能是一种选择。
局限性
- 证据来自大鼠模型,尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Owing to patient intolerance or drug interactions, alternative agents to rifampin are needed for management of staphylococcal periprosthetic joint infection. In the current study, we evaluated rifabutin, rifapentine and rifampin, with and without vancomycin, in a rat model of foreign body osteomyelitis. METHODS: Proximal tibiae were inoculated with methicillin-resistant Staphylococcus aureus (MRSA) and a Kirschner wire (K-wire) implanted in each. After 4 weeks of infection, rifampin, rifabutin, or rifapentine were administered, alone or with vancomycin. Tibiae and K-wires were cultured, and medians were reported as log10 colony-forming units (CFUs) per gram of bone or log10 CFUs per K-wire, respectively. RESULTS: Rifampin, rifabutin or rifapentine administered with vancomycin yielded less MRSA from bones (0.10, 3.02, and 0.10 log10 CFUs/g, respectively) than did no treatment (4.36 log10 CFUs/g) or vancomycin alone (4.64 log10 CFUs/g) (both P ≤ .02). The K-wires of animals receiving no treatment or vancomycin monotherapy recovered medians of 1.76 and 2.91 log10 CFUs/g per K-wire, respectively. In contrast, rifampin, rifabutin and rifapentine administered with vancomycin yielded medians of 0.1 log10 CFUs per K-wire, respectively. Rifampin resistance was detected in a single animal in the rifampin monotherapy group. CONCLUSIONS: Rifabutin or rifapentine with vancomycin were as active as rifampin with vancomycin against MRSA in rat foreign body osteomyelitis, suggesting that rifabutin and/or rifapentine may be alternatives to rifampin in the clinical management of staphylococcal periprosthetic joint infections.
引用
- Karau MJ, Schmidt-Malan SM, Albano M, et al. Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis. J Infect Dis. 2020. PMID: 32914837. doi:10.1093/infdis/jiaa401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。